Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
| ▸ | POLG | P54098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6531278 | 0.86 | CYP3A4 (0.32) | TYMP | |
| SCHEMBL6530713 | 0.77 | KDM4E (0.37) | TYMP | |
| SCHEMBL6530428 | 0.77 | ADORA2B (0.40) | TYMP | |
| SCHEMBL3793139 | 0.76 | PDE4D (0.40) | PDE4DPDE3ASLC29A1ST6GAL1TYMP | |
| SCHEMBL383446 | 0.76 | PDE4D (0.46) | PDE4DPDE3ASLC29A1ST6GAL1TYMP | |
| SCHEMBL10693710 | 0.74 | ST6GAL1 (0.38) | ST6GAL1TYMP | |
| SCHEMBL8598173 | 0.71 | NT5E (0.43) | ST6GAL1TYMP | |
| SCHEMBL384131 | 0.71 | ST6GAL1 (0.39) | ST6GAL1TYMP | |
| SCHEMBL1318619 | 0.70 | NT5E (0.45) | ST6GAL1TYMP | |
| SCHEMBL1317526 | 0.70 | NT5E (0.45) | ST6GAL1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050266422-A1 | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides | SIRNA THERAPEUTICS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266422-A1 | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides | NSUN3, IRF3, SNRPF | PDE4D 2941/4885PDE3A 3281/4885SLC29A1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.